CompletedNot Applicable

Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain

United States275 participantsStarted 2019-09-25

Plain-language summary

Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients age ≥18 years with chronic musculoskeletal pain (pain present for 3 or more months) treated with prescription opioids on most days in the past 3 months. Exclusion Criteria: * Patients who are non-English speaking, * Patients who are incarcerated * Patients who are unable to provide consent will be excluded.

What they're measuring

PROMIS Pain Interference 6b

Timeframe: Baseline

Opioid Risk Tool

Timeframe: Baseline

PROMIS Short Form v1.0-Prescription Pain Medication Misuse

Timeframe: Baseline

Trial details

NCT IDNCT03947749

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-04-05

View on ClinicalTrials.gov More Pain, Chronic trials